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Background: Inflammatory bowel disease (IBD) is characterized by a chronic relapsing 
inflammation of the gastrointestinal tract. Adult IBD patients suffer from a disabling disease 
which greatly affects health-related quality of life (HRQoL). A worse HRQoL in these patients 
may result in a defensive and ineffective use of medical attention and thus higher medical costs. 
Because of its chronic nature, IBD may also cause psychological problems in many patients 
which may also influence HRQoL and care-seeking behavior. An important factor reducing 
HRQoL is disease activity. Induction of remission and long-term remission are important 
goals for improving HRQoL. Furthermore, remission is associated with a decreased need for 
hospitalization and surgery and increased employment, which in turn improve HRQoL. Treatment 
strategies available for many years are corticosteroids, 5-aminosalicylates and immunnosup-
pressants, but these treatments did not show significant long-term improvement on HRQoL. The 
biologics, which induce rapid and sustained remission, may improve HRQoL.
Objective: To review and evaluate the current literature on the effect of biologics on HRQoL 
of IBD patients.
Methods: We performed a MEDLINE search and reviewed the effect of different biologics on 
HRQoL. The following subjects and synonyms of these terms were used: inflammatory bowel 
disease, Crohn’s disease, ulcerative colitis, quality of life, health-related quality of life, fatigue, 
different anti-TNF medication, and biologicals/biologics (MESH). Studies included were limited 
to English-language, adult population, full-text, randomized, double-blind, placebo-controlled 
in which HRQoL was measured.
Results:  Out of  202 identified articles, 8 randomized controlled trials (RCT) met the inclusion criteria. 
Two RCTs on infliximab showed significant improvement of HRQoL compared to placebo which was 
sustained over the long term. One RCT on adalimumab showed a significant and sustained improvement of 
HRQoL compared to placebo. This study showed also significant decrease of  fatigue in the adalimumab-
treated patients. Three RCTs on certolizumab showed a significant improvement of  HRQoL in the inter-
vention group compared to placebo. Two RCTs of natalizumab treatment were found. One study showed 
significant and sustained improvement compared to placebo, and also scores of HRQoL comparable 
to that in the general population, but in the other no significant results were found.
Conclusion: The biologics infliximab, adalimumab, certolizumab, and natalizumab demon-
strated significant improvement of HRQoL of IBD patients compared with placebo. However, 
we found differences in improvement of HRQoL between the different biologics.
Keywords: inflammatory bowel disease, health-related quality of life, health care costs, biologics
Introduction
Inflammatory bowel disease (IBD) is characterized by a chronic relapsing inflammation 
of the gastrointestinal tract.Clinical and Experimental Gastroenterology 2009:2 102
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Treatment with expensive biologics will increase the up 
front health care costs for IBD, however they can be cost-
effective due to rapid induction and long-term remission.22 
In order to reduce indirect costs, biologics must improve 
HRQoL. We therefore focus our review on the effect of these 
drugs on HRQoL.
Methods
Search
In MEDLINE we searched (from 1980 up to January 2009) 
for the following subjects and synonyms: inflammatory bowel 
disease (MESH), Crohn’s disease (MESH), ulcerative colitis 
(MESH), quality of life (MESH), health related quality of 
life, fatigue (MESH), infliximab, adalimumab, certolizumab 
and natalizumab, and biologicals/biologics (MESH). We also 
hand-searched the reference lists of the relevant articles for 
titles which included a biologic and quality of life.
The search was limited to English-language, adult 
population and full-text publications. Studies were included 
for review if they were randomized, double blind, placebo-
controlled trials (RCTs) of biologics (ie: infliximab, 
adalimumab, certolizumab or natalizumab) maintenance 
treatment in IBD and if HRQoL was measured by the Inflam-
matory Bowel Disease Questionnaire (IBDQ) and/or the 
Short Form Health Survey (SF-36) as a primary or secondary 
outcome measurement. Only studies using these question-
naires were included, because in current research these are 
the most commonly used validated questionnaires, enabling 
reliable comparison of the study outcomes.43–46 We included 
only randomized, double blind, placebo-controlled trials, 
to rule out confounding of the results by placebo effects or 
physician preference for biologics.
Questionnaires
The IBDQ is a disease-specific HRQoL questionnaire 
containing 4 subscales: bowel symptoms, systemic 
symptoms, emotional functioning, and social functioning.43 
The total IBDQ score is the sum of the responses to each 
of the IBDQ questions. Total IBDQ score can range from 
32 (very poor HRQoL) to 224 (perfect HRQoL). Patients 
in symptomatic remission usually have a score of 170 or 
greater.43 An absolute change of 16 points in the total IBDQ 
score has been used to define a minimum clinically relevant 
improvement.43,47,48
The SF-36 is a generic HRQoL assessment and is also 
much used in IBD studies. The SF-36 consists of 8 scales 
(physical functioning, role-physical, bodily pain, general 
health, vitality, social functioning, role-emotional, and mental 
Although IBD is a chronic disease with a normal life 
expectancy, the disease decreases health-related quality of 
life (HRQoL). Adult IBD patients have a lower HRQoL 
than the general population. A reduction of HRQoL can be 
predicted by symptom severity, disease severity, rheumatic 
symptoms, female gender and higher need for hospitalization. 
The chronic nature of the disease also affects HRQoL. The 
long period of time needed to adapt to the disease may cause 
psychological symptoms which negatively influence HRQoL 
and care-seeking behavior.1–7
IBD patients frequently complain of fatigue. Approxi-
mately 41% patients with quiescent IBD are known to 
suffer from fatigue,8 which is frequently associated with a 
decreased HRQoL.
In a substantial group of IBD patients HRQoL may 
impaired because of prolonged treatment and the adverse 
effects associated with such treatment, the need for surgery 
and hospitalization.9–15 Another important factor influencing 
HRQoL is disease activity.16–20 Improvement of HRQoL can 
therefore be achieved by inducing remission.21 Furthermore, 
remission is associated with less medical care, increased 
employment, and thus improved HRQoL.22
For decades, 5-aminosalicylates (5-ASA), corticosteroids 
and immunosuppressants comprised the cornerstone of 
treatment for IBD patients. Despite their effectiveness in 
active disease, these drugs cannot prevent progression to a 
more complicated disease.23 Although IBD patients showed 
significant improvement of HRQoL on the short term, during 
prolonged treatment no significant improvement of HRQoL 
has been shown with these drugs,9,24–31 partly because of side 
effects that also negatively affect HRQoL.11–13,32
Because current treatments fail to prevent progression to 
more complicated disease stages, and because of the negative 
influence of the disease and its treatment on HRQoL, a more 
effective treatment is needed.5,9,15,16,19,32,33 Biologics, which 
induce rapid and sustained disease remission, may provide 
effective treatment.34
However, biologics are more expensive than 5-ASA, 
corticosteroids and immunosuppressants used for treating 
IBD. IBD has high direct and indirect costs for patients and 
society. The direct costs (±50%) comprise inpatient care, 
outpatient care, self-care, medications and tests/procedures. The 
indirect costs comprise work absenteeism, decreased incomes, 
decreased HRQoL and fatigue. The direct costs vary between 
€6,000 and €40,000 per patient year.35,36–38 In the near future, 
the costs for IBD will increase, largely because of the increased 
incidence rates of IBD over recent decades in developed 
countries together with the early onset of the disease.38–42Clinical and Experimental Gastroenterology 2009:2 103
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health). The SF-36 comprises two summary components, the 
physical component summary (PCS) and the mental com-
ponent summary (MCS) which are derived from individual 
scale scores.44–46 The 8 scales are scored on a scale of 0 to 
100, higher scores indicating better health.49 For the PCS and 
the MCS the mean score is 50 and the SD 10 for the general 
population in the US.50
An absolute increase of 3 to 5 points in the PCS or MCS 
scale is generally accepted as a meaningful change.51,52
Results
The literature search identified 202 potentially eligible 
articles. Of these, 143 were not focused on HRQoL. Fifty 
studies were excluded because they were not RCTs. Of the 
9 remaining studies, we excluded 1 RCT which reported 
results from only a single infusion of infliximab.53 The first 
author determined which studies were excluded and an 
inter-rater agreement check of 10% of the articles was done 
by the last author. A perfect agreement was reached in this 
random sample.
Table 1 summarizes the studies, which are discussed 
below.
Infliximab and HRQoL
Two studies, the Active Ulcerative Colitis Trials 1 and 2 
(ACT 1 and 2) and the ACCENT 1 study (Crohn’s disease), 
investigated the effect of infliximab on the HRQoL.54,55
The ACT 1 and 2 compared infliximab 5 mg/kg with 
10 mg/kg and a placebo-controlled group. Both the ACT 1 
and ACT 2 studies showed a significant improvement of total 
IBDQ and SF-36 scores at week 8 compared with baseline in 
both the infliximab 5 mg/kg and 10 mg/kg groups. There were 
no differences in HRQoL between the 2 treatment groups. 
The improvement in HRQoL was significantly greater in 
the treatment groups than in the placebo-control group for 
the IBDQ (P  0.05) and the SF-36 (P  0.01). Also, the 
percentage of patients achieving clinically relevant improve-
ment on the IBDQ and SF-36 was significantly greater in 
the treatment groups than in the placebo-controlled group 
(P  0.05). The bowel and social domain scores seemed to 
be responsible for the improvement of the IBDQ, whereas 
both PCS and MCS of the SF-36 scores were responsible for 
the improvement. At 30 and 54 weeks the improvement in 
the treatment groups was still significantly greater than in 
the placebo-controlled group (P  0.001).
The ACCENT I study compared 3 treatment modalities 
(single infusion of 5 mg/kg with placebo maintenance; 5 mg/kg 
single infusion with 5 mg/kg maintenance; 5 mg/kg single 
infusion with 10 mg/kg maintenance). In all 3 treatment 
groups, all 4 IBDQ dimensional scores (emotional func-
tioning, social functioning, systemic symptoms and bowel 
symptoms dimensions) improved from baseline throughout 
the study. However, the improvement in total IBDQ score 
at week 10, 30, and 54 was consistently larger (P  0.05) 
in both infliximab maintenance groups compared with the 
placebo maintenance group. The IBDQ subscales for bowel 
and systemic symptoms showed the largest improvement. 
The SF-36 scores improved from baseline to week 54 in 
all treatment groups. The summary scale PCS improved 
significantly in both infliximab groups (P  0.05). The 
summary scale MCS improved significantly in the 10 mg/kg 
infliximab group (P  0.05). The PCS scale improved more 
than the MCS scale.
Adalimumab and HrQoL
The CHARM study investigated the effect of adalimumab 
on HRQoL and fatigue.56 This study compared 3 arms. Every 
treatment arm started with 80 mg induction of adalimumab 
followed by 40 mg at week 2. At week 4, patients followed 
the treatment arm for which they were randomized: 40 mg 
adalimumab every other week (eow) for 1 year, 40 mg 
adalimumab every week for 1 year, or placebo injections. 
The analyses included only the 499 patients responding 
to treatment at week 4. Induction therapy of adalimumab 
significantly improved HRQoL (P  0.0001).
The IBDQ significantly improved in the adalimumab 
groups up to 1 year later (P  0.001 for adalimumab eow 
and P  0.05 for adalimumab weekly).
No differences were found between both maintenance 
groups. The systemic and social domains were particularly 
responsible for the improvement of the IBDQ. On the SF-36, 
patients in the 40 mg every other week group showed signifi-
cantly more improvement on PCS and MCS at 1 year than 
the induction-only group (P  0.05). The 40-mg-every-week 
group did not show a significantly greater improvement than 
the induction-only group. The 2 maintenance groups did 
not differ significantly. Finally, both maintenance groups 
reported fewer fatigue symptoms than the placebo group 
(0.05  P  0.001).
Certolizumab and HrQoL
Three studies investigated the effect of certolizumab pegol 
on HRQoL (Table 1).57–59
In the first study patients received either 100 mg, 200 mg, 
400 mg, or placebo at weeks 0, 4, and 8. HRQoL was mea-
sured with the IBDQ for 3 months.57 Analyses focused on the Clinical and Experimental Gastroenterology 2009:2 104
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400 mg group, because this dose was identified in another 
study as the most effective dose.60 HRQoL improved sig-
nificantly from baseline to 12 weeks follow-up (P  0.05), 
and significantly more than in the placebo group at all time 
points (P  0.05). On the subscales of the IBDQ, at 12 weeks 
patients receiving 400 mg certolizumab reported significantly 
more improvement on emotional functioning and systemic 
functioning compared with the placebo group. No significant 
differences were found at 12 weeks for bowel functioning 
and social functioning.
Table 1 Demographic and baseline characteristics
Study n Crohn’s disease/
ulcerative colitits
Age, years (mean ± SD) Sex male, number (%) CDAI (mean ± SD) baseline Total IBDQ  
score (mean ± SD) 
baseline
Total SF-36  
score (mean ± SD)   
baseline
Intervention 
 
Control group 
Feagan 200754 728 Ulcerative colitis Placebo: 40.3 ± 13.6 291 (40) 126 ± 31.7 PCS: 38.4 ± 8.5 Group 1:  
Infliximab: 5 mg/kg wk 0, 2, 6; 
maintenance every 8 wk
Placebo
Infliximab (5 mg/kg): 41.5 ± 13.7
 
Infliximab (10 mg/kg): 41.0 ± 41.1
MCS: 40.3 ± 11.5 Group 2: 
infliximab: 10 mg/kg wk 0, 2, 6; 
maintenance every 8 wk
Feagan 200761 
(ENACT-2)
339 Crohn’s disease Natalizumab: 37 ± 13 Natalizumab: 77 (46) Natalizumab: 296 ± 56 123.6 ± 29.7 PCS: 33.7 ± 8.0 Natalizumab induction (300 mg) 
or placebo wk 0, 4, 8
Placebo
Placebo: 37 ± 12 Placebo: 59 (35) Placebo: 302 ± 58 MCS: 38.4 ± 10.9 responders: Natalizumab  
(300 mg/4 wk)
Feagan 200355 573 Crohn’s disease 37 ± 12 (all patients) 239 (41.7) 302 ± 54 128 ± 27 PCS: 34 ± 8 Infliximab induction (5 mg/kg) wk 0 
responders:
Placebo
MCS: 39 ± 11 Group 1:  
Infliximab (5 mg/kg) wk 2,6; 
maintenance every 8 wk
Group 2:  
infliximab(5 mg/kg) wk 2, 6; 
maintenance (10 mg/kg) every 8 wk
Loftus 200856 499 Crohn’s disease Group 1: 36.9 ± 11.9
Group 2: 36.4 ± 11.1
Group 3: 36.9 ± 11.8
Group 1: 65 (38)
Group 2: 61 (36)
Group 3: 62 (39)
Group 1: 321.1 ± 67.1
Group 2: 315.7 ± 61.5
Group 3: 312.6 ± 58.3
124.6 ± 28.7 PCS: 36.9 ± 7.6
MCS: 37.6 ± 10.8
Adalimumab induction (80 mg) 
wk 0, 2  
responders:
Group 1:
Adalimumab (40 mg/every 
other week)
Group 2: adalimumab (40 mg/wk)
Placebo
rutgeerts 200857 292 Crohn’s disease Placebo: 35.8 (range 19–64)  
certolizumab 100 mg:  
33.5 (range 18– 56)/200 mg:  
40.1 (range 19–71)/400 mg:  
35.9 (18–67)
Placebo: 24 (32.9) certolizumab 
100 mg: 35 (47.3)/200 mg: 
22 (30.6)/400 mg: 32 (44.4)
Placebo: 291.5 (206–448)/
certolizumab 100 mg: 299.2 
(194–520)/200 mg: 310.7 
(184–446)/400 mg: 304.5 (204–461)
126.1 ± 27.4 Group 1: certolizumab (100 mg)  
wk 0, 4, 8
Group 2: certolizumab (200 mg)  
wk 0, 4, 8
Group 3: certolizumab (400 mg)  
wk 0, 4, 8
Placebo
Sands 200762 79 Crohn’s disease Natalizumab + infliximab: 39.9 ± 12.6
Placebo + infliximab: 38.9 ± 13.2
Natalizumab + infliximab: 24 (46)
Placebo + infliximab: 17 (63)
Natalizumab + infliximab: 263.8 ± 89.3
Placebo + infliximab: 243.6 ± 57.1
Not mentioned Natalizumab (300 mg) wk 0, 4, 8 + 
infliximab (5 mg/kg) single doses 
at wk 6
Placebo + 
infliximab (5 mg/kg) 
single doses at 
week 6
Sanborn 200758 
(PrECiSE)
662 Crohn’s disease Certolizumab: 37 ± 12 Certolizumab: 157 (47) Certolizumab: 301 ± 62 Not mentioned Certolizumab 400 mg) wk 0, 2, 4; 
maintenance (400 mg) every 4 wk
Placebo
Placebo: 38 ± 12 Placebo: 131 (40) Placebo: 306 ± 61 Placebo: wk 0, 2, 4; maintenance  
every 4 wk
Sanborn 200758 
(PrECiSE 2)
668 Crohn’s disease Certolizumab: 38 ± 11
Placebo: 38 ± 12
Certolizumab: 92 (43)
Placebo: 109 (52)
Certolizumab: 300 ± 64
Placebo: 297 ± 62
Not mentioned Certolizumab induction (400 mg)  
wk 0, 2, 4
responders: maintenance (400 mg)  
every 4 wk or
Placebo: maintenance every 4 wk
Placebo
Abbreviations: CDAI, Crohn’s Disease Activity Index; IBDQ, Inflammatory Bowel Disease Questionnaire; MCS, mental component summary; PCS,  physical component 
summary; SF-36, Short-Form Health Survey; N, number of patients.Clinical and Experimental Gastroenterology 2009:2 105
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The PRECISE 1 and 2 studies investigated the 
efficacy of certolizumab pegol treatment and the efficacy 
of the maintenance of this treatment, respectively. 
The studies included also measurements of the HRQoL 
with the IBDQ.58,59
The PRECISE 1 study patients received either 400 mg 
certolizumab pegol or placebo at weeks –0, –2, and 4 followed 
by every 4 weeks through week 26.58 The HRQoL increased 
from baseline to week 26, and in the certolizumab group 
significantly more than in the placebo group (P = 0.03).58
Table 1 Demographic and baseline characteristics
Study n Crohn’s disease/
ulcerative colitits
Age, years (mean ± SD) Sex male, number (%) CDAI (mean ± SD) baseline Total IBDQ  
score (mean ± SD) 
baseline
Total SF-36  
score (mean ± SD)   
baseline
Intervention 
 
Control group 
Feagan 200754 728 Ulcerative colitis Placebo: 40.3 ± 13.6 291 (40) 126 ± 31.7 PCS: 38.4 ± 8.5 Group 1:  
Infliximab: 5 mg/kg wk 0, 2, 6; 
maintenance every 8 wk
Placebo
Infliximab (5 mg/kg): 41.5 ± 13.7
 
Infliximab (10 mg/kg): 41.0 ± 41.1
MCS: 40.3 ± 11.5 Group 2: 
infliximab: 10 mg/kg wk 0, 2, 6; 
maintenance every 8 wk
Feagan 200761 
(ENACT-2)
339 Crohn’s disease Natalizumab: 37 ± 13 Natalizumab: 77 (46) Natalizumab: 296 ± 56 123.6 ± 29.7 PCS: 33.7 ± 8.0 Natalizumab induction (300 mg) 
or placebo wk 0, 4, 8
Placebo
Placebo: 37 ± 12 Placebo: 59 (35) Placebo: 302 ± 58 MCS: 38.4 ± 10.9 responders: Natalizumab  
(300 mg/4 wk)
Feagan 200355 573 Crohn’s disease 37 ± 12 (all patients) 239 (41.7) 302 ± 54 128 ± 27 PCS: 34 ± 8 Infliximab induction (5 mg/kg) wk 0 
responders:
Placebo
MCS: 39 ± 11 Group 1:  
Infliximab (5 mg/kg) wk 2,6; 
maintenance every 8 wk
Group 2:  
infliximab(5 mg/kg) wk 2, 6; 
maintenance (10 mg/kg) every 8 wk
Loftus 200856 499 Crohn’s disease Group 1: 36.9 ± 11.9
Group 2: 36.4 ± 11.1
Group 3: 36.9 ± 11.8
Group 1: 65 (38)
Group 2: 61 (36)
Group 3: 62 (39)
Group 1: 321.1 ± 67.1
Group 2: 315.7 ± 61.5
Group 3: 312.6 ± 58.3
124.6 ± 28.7 PCS: 36.9 ± 7.6
MCS: 37.6 ± 10.8
Adalimumab induction (80 mg) 
wk 0, 2  
responders:
Group 1:
Adalimumab (40 mg/every 
other week)
Group 2: adalimumab (40 mg/wk)
Placebo
rutgeerts 200857 292 Crohn’s disease Placebo: 35.8 (range 19–64)  
certolizumab 100 mg:  
33.5 (range 18– 56)/200 mg:  
40.1 (range 19–71)/400 mg:  
35.9 (18–67)
Placebo: 24 (32.9) certolizumab 
100 mg: 35 (47.3)/200 mg: 
22 (30.6)/400 mg: 32 (44.4)
Placebo: 291.5 (206–448)/
certolizumab 100 mg: 299.2 
(194–520)/200 mg: 310.7 
(184–446)/400 mg: 304.5 (204–461)
126.1 ± 27.4 Group 1: certolizumab (100 mg)  
wk 0, 4, 8
Group 2: certolizumab (200 mg)  
wk 0, 4, 8
Group 3: certolizumab (400 mg)  
wk 0, 4, 8
Placebo
Sands 200762 79 Crohn’s disease Natalizumab + infliximab: 39.9 ± 12.6
Placebo + infliximab: 38.9 ± 13.2
Natalizumab + infliximab: 24 (46)
Placebo + infliximab: 17 (63)
Natalizumab + infliximab: 263.8 ± 89.3
Placebo + infliximab: 243.6 ± 57.1
Not mentioned Natalizumab (300 mg) wk 0, 4, 8 + 
infliximab (5 mg/kg) single doses 
at wk 6
Placebo + 
infliximab (5 mg/kg) 
single doses at 
week 6
Sanborn 200758 
(PrECiSE)
662 Crohn’s disease Certolizumab: 37 ± 12 Certolizumab: 157 (47) Certolizumab: 301 ± 62 Not mentioned Certolizumab 400 mg) wk 0, 2, 4; 
maintenance (400 mg) every 4 wk
Placebo
Placebo: 38 ± 12 Placebo: 131 (40) Placebo: 306 ± 61 Placebo: wk 0, 2, 4; maintenance  
every 4 wk
Sanborn 200758 
(PrECiSE 2)
668 Crohn’s disease Certolizumab: 38 ± 11
Placebo: 38 ± 12
Certolizumab: 92 (43)
Placebo: 109 (52)
Certolizumab: 300 ± 64
Placebo: 297 ± 62
Not mentioned Certolizumab induction (400 mg)  
wk 0, 2, 4
responders: maintenance (400 mg)  
every 4 wk or
Placebo: maintenance every 4 wk
Placebo
Abbreviations: CDAI, Crohn’s Disease Activity Index; IBDQ, Inflammatory Bowel Disease Questionnaire; MCS, mental component summary; PCS,  physical component 
summary; SF-36, Short-Form Health Survey; N, number of patients.Clinical and Experimental Gastroenterology 2009:2 106
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The PRECISE 2 study patients received induction 
therapy of certolizumab pegol 400 mg at weeks -0, -2, 
and 4. Patients with a clinical response at week 6 were 
included in the intervention group (certolizumab 400 mg 
every 4 weeks) or the placebo group (placebo every 4 weeks) 
and received injections through week 24. The IBDQ was 
measured at weeks 0, -6, -16, and 26. The scores of the 
IBDQ were significantly higher in the intervention group 
(certolizumab 400 mg) than the control group (P = 0.007) 
at week 26.59
Natalizumab and HrQoL
For the effect of natalizumab on HRQoL, which is registered 
for the treatment of Crohn’s disease in the US only, 2 studies 
were included (Table 1).61,62
The first study investigated the combination therapy of 
infliximab (5 mg/kg) at weeks –10, –2, and 6 and natalizumab 
(300 mg) at weeks 0, 4 and 8 compared with infliximab 
(5 mg/kg) and placebo. The combination therapy of natali-
zumab and infliximab showed a similar increase of the IBDQ 
compared with the combination of infliximab and placebo in 
CD patients (P = 0.811).62
Another study (ENACT-2) followed up on patients 
responding to natalizumab with continued treatment (300 mg 
infusions every 4 weeks up to 48 weeks) or placebo. HRQoL 
was not reported in the ENACT-1 study. In the follow-up 
study, it was reported that the scores of patients had already 
improved from baseline to inclusion in the ENACT-2 study. 
From inclusion in the follow-up study to 60 weeks, patients in 
the intervention group showed significantly greater increase 
in IBDQ total score and subscale scores at all time points 
than the placebo group (0.05  P  0.001). The highest 
percentages of patients who exceeded the minimally impor-
tant difference on the 4 subscales of the IBDQ were seen in 
the bowel and social domains.
The SF-36, PCS and MCS scores improved significantly 
more in the intervention group than the placebo group at 
weeks 48 and 60 (P  0.01).
Of particular note in this study is that the SF-36 profile 
of the natalizumab group was similar to the profile of the 
general population.61
Disease activity and HrQoL
HRQoL appears to be related to disease activity in the articles 
that studied this relationship. ACT 1 and 2 (infliximab) 
showed that response or remission (Mayo subscore) was 
correlated with improvement of IBDQ and SF-36.54,63 
ACCENT 1 (infliximab) showed significant correlations 
between the IBDQ scores and Crohn’s disease activity index 
(CDAI) scores at week 54.54,63
For certolizumab, CDAI score was correlated positively 
with IBDQ score.57 This study showed that the clinical efficacy 
of certolizumab pegol in patients with moderate-to-severe 
Crohn’s disease is paralleled by improvement in HRQoL.
Discussion
Adult IBD patients suffer from a chronic disease with an 
impaired HRQoL. Impairment of HRQoL and in particular 
fatigue in patients may result in a defensive and ineffective 
use of medical resources. Therefore impaired HRQoL may 
lead to more frequent visits, more tests and often variable 
treatment, and thus higher medical costs.8,64–66 It is expected 
that improvement of HRQoL will redirect medical attention-
seeking behavior of patients, resulting in a more cost-effective 
way of treating these patients. Therapeutic strategies that 
have been available for many years include corticosteroids, 
5-aminosalicylates and immunnosuppressants. However, 
no significant long-term improvement has been seen on 
HRQoL with these therapies. More recently, biologics have 
been introduced in the treatment of IBD. Individual studies 
report favorable results of biologics on HRQoL.
This present review showed that 7 studies report a 
significant improvement of HRQoL (IBDQ and/or SF-36) 
in patients treated with a variety of biologics compared to 
placebo. One study reported on the use of 2 biologics. This 
study found no incremental effect on HRQoL of natalizumab 
over infliximab.
Although all biologics improve HRQoL, we found 
differences in the effect on HRQL between different 
biologics. On the IBDQ, adalimumab, natalizumab and 
certolizumab all improved HRQoL to a level of patients in 
remission (170 points). Infliximab showed improvement 
on total IBDQ score (improvement with 16 points), but not 
to a total score above 170 points. Further differences were 
shown in the SF-36 profiles. Patients using natalizumab had 
a profile comparable with that of the general population. 
Patients using infliximab, adalimumab or certolizumab did 
not have such a profile.
The reason for the differences in effect on HRQoL between 
the biologics is unclear. One hypothesis is that the differences 
found may be due to the route of administration of these 
drugs. Infliximab is given in the outpatient setting or in the 
hospital intravenously, while certolizumab and adalimumab is 
administered subcutaneously at home. However, natalizumab, 
which is also administered intravenously, demonstrated the 
greatest improvement on HRQoL.Clinical and Experimental Gastroenterology 2009:2 107
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Another explanation for the differences found could 
be that the patients included in the different studies are 
not comparable. For instance, CDAI scores at baseline 
were lower in the intervention group of the natalizumab 
study (ENACT 2) than in the intervention groups of 
the infliximab, adalimumab and certolizumab studies. 
Baseline IBDQ and SF-36 scores were also lower in the 
natalizumab study (ENACT 2) than in the infliximab, 
adalimumab and certolizumab studies (except MCS score 
of the SF-36 in the adalimumab study) (Table 1). These 
differences are in contrast of what is expected, because 
natalizumab increased IBDQ scores up to a level of 
patients in remission.
Although fatigue is one of the factors that alter HRQoL 
in IBD patients, leading to increased costs and occurring in 
a high percentage of IBD patients, only one study reported 
the effects of treatment on fatigue.8,56 In the CHARM study 
adalimumab significantly decreased fatigue.56 Further 
research is needed to investigate the long-term effects of 
other biologics on fatigue.
Although all drugs appeared to have beneficial effects 
on HRQoL, a limitation of our review is that the number of 
studies included in this review is low. Therefore no definitive 
conclusions on the influence of biologics on the different 
dimensions of the IBDQ can be made yet.
With that caveat in mind, it appears that treatment with 
biologics particularly improves the bowel, systemic and 
social domains of the IBDQ. Emotional functioning seems 
to be less responsive to biologics.
Another limit is that the studies included in this review 
included only patients with active disease and most studies 
included only patients with moderate-to-severe disease. 
This could bias the outcome, since more improvement is 
feasible in patients with a low HRQoL than in patients with a 
high HRQoL. Whether biologics have comparable favorable 
results in patients with limited disease needs to be studied 
separately.
Expert opinion
In recent years awareness of the importance of HRQoL has 
increased, not only for the benefit of the patients but also 
for reducing health care costs in IBD. However, research 
on the magnitude of fatigue, which is an important factor 
in altering HRQoL and the health care costs, is limited in 
IBD patients.
Biologics increase health care costs and in the near 
future newer expensive biologics will be introduced. 
Because biologics can induce and sustain remission and 
therefore improve HRQoL, these strategies are expected to 
be cost-effective despite the high costs of treatment with 
biologics.
For future therapeutic strategies more research is needed 
on HRQoL and fatigue and the influence of newer therapeutic 
agents on different domains of HRQoL. Furthermore, studies 
must increase the duration of follow-up to investigate whether 
the new biologics are capable of sustaining the short-term 
benefits on HRQoL in IBD patients.
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